Subtitle: Emerging Immuno-Oncology Target, Placental Immune Tolerance Mechanisms, and High-Purity Viral Envelope Reagents for Cancer Immunotherapy Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for ERVV-2 (Suppressyn) drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | ERVV-2 ECD-Fc Fusion Protein HEK293 Expressed, High purity (>95%), Endotoxin <1 EU/μg. Sequence Verified. Native glycosylation pattern preserved. |
View ERVV-2 Products |
| Gene Delivery | ERVV-2 Premade Lentivirus Particles Full-length ORF with native signal peptide for stable cell line construction. Suitable for membrane expression studies. |
View ERVV-2 Products |
| Benchmark Ab | Anti-ERVV-2 Reference Antibody Recombinant monoclonal positive control for assay validation. |
View ERVV-2 Products |
| Validator | ERVV-2 siRNA Set (3 unique sequences) For knockdown verification and specificity controls. |
View ERVV-2 Products |
| Related Target A | HERV-K (ERVK-6) Synergistic endogenous retroviral target often co-reactivated in oncogenesis; potential cross-reactivity screening required. |
View ERVK-6 Products |
| Related Target B | HLA-G Functional analog in placental immune tolerance; complementary checkpoint pathway. |
View HLA-G Products |
| Related Target C | PD-L1 (CD274) Established immune checkpoint; ERVV-2 represents novel non-PD-1/PD-L1 axis for combination therapy. |
View PD-L1 Products |
Critical Assay Challenges & Technical Specifications
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Glycosylation-dependent Epitopes | HEK293 Expressed (Native Glycosylation) to ensure proper structural folding. |
| Cross-reactivity with HERV family proteins (ERVK, ERVW, ERV3) | Strict sequence homology analysis; viral family protein panel available for selectivity screening with >95% purity. |
| Conformational epitope integrity (envelope protein folding) | HEK293 expression system ensuring native disulfide bond formation; Theoretical MW verification by mass spectrometry. |
| Membrane topology validation for immune synapse assays | Lentivirus delivery system for stable, physiological surface expression; Endotoxin controlled <1 EU/μg for sensitive immune cell assays. |
| Lack of functional blocking controls / False Positives | Validated siRNA included for loss-of-function specificity verification and reduction of false positives in cellular assays. |
Live ERVV-2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
- ➤ View Active Clinical Trials
- ➤ Latest Research & Biology (ERVV-2 cancer)
- ➤ Suppressyn Oncology Publications
- ➤ Latest Resistance Research
- ➤ Recent Patent Filings
Global Clinical Landscape & Future Outlook
The race for ERVV-2 (Suppressyn) therapeutics represents a paradigm shift toward endogenous retroviral targets in immuno-oncology. As researchers uncover the reactivation of ERVV-2 in specific solid tumors (colorectal, lung, ovarian) and placental-related pathologies, major players are exploring targeted immunotherapies. Currently positioned in preclinical and early discovery phases, this target offers a novel mechanism distinct from traditional immune checkpoints. The next wave of R&D is heavily focused on exploiting these tumor-associated antigens (TAAs) through antibody-drug conjugates (ADCs), T-cell engagers, and combination regimens with existing PD-1/PD-L1 inhibitors. High specificity reagents are critical to avoid cross-reactivity with healthy tissues and other HERV family members.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody (Blocking) | Emerging biotechs, Academic labs (Stanford, UCSF) | Solid Tumors (Colorectal, Lung), Placental pathology | Receptor binding inhibition assays requiring high-purity ECD-Fc with native conformation. |
| Bispecific T-cell Engager | Preclinical discovery programs | Hematological malignancies | Cell-based killing assays using lentivirus-transduced target cells expressing full-length ERVV-2. |
| CAR-T (Targeting ERVV-2+ cells) | Academic research hospitals | Ovarian, Endometrial cancers | Stable expression cell lines via lentivirus; Flow cytometry validation standards. |
| ADC (Antibody-Drug Conjugate) | Early exploratory stage | ERVV-2-high solid tumors | Internalization assays using surface-expressed lentivirus constructs. |